{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:55:13Z","timestamp":1776660913094,"version":"3.51.2"},"reference-count":32,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10262","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T20:30:00Z","timestamp":1622752200000},"source":"Crossref","is-referenced-by-count":8,"title":["Co\u2011administration of obeticholic acid and simvastatin protects against high\u2011fat diet\u2011induced non\u2011alcoholic steatohepatitis in mice"],"prefix":"10.3892","volume":"22","author":[{"given":"Wen-Cong","family":"Li","sequence":"first","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Xian","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Guang","family":"Ren","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Guo","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Bo","family":"Kong","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Shan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Min","family":"Nan","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"key20210729112048_b1-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"key20210729112048_b2-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"key20210729112048_b3-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3760\/cma.j.issn.1007-3418.2018.03.008","article-title":"Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update","volume":"26","year":"2018","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"key20210729112048_b4-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology"},{"key":"key20210729112048_b5-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"key":"key20210729112048_b6-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","article-title":"Current efforts and trends in the treatment of NASH","volume":"62 (Suppl 1)","author":"Ratziu","year":"2015","journal-title":"J Hepatol"},{"key":"key20210729112048_b7-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol Rev"},{"issue":"33453","key":"key20210729112048_b8-etm-0-0-10262","doi-asserted-by":"publisher","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"key":"key20210729112048_b9-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.taap.2016.11.006","article-title":"Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation","volume":"314","author":"Zhang","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"key20210729112048_b10-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"key20210729112048_b11-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"105803","key":"key20210729112048_b12-etm-0-0-10262","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"key20210729112048_b13-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejphar.2017.11.021","article-title":"Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model","volume":"818","author":"Briand","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"key20210729112048_b14-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver","volume":"59","author":"Papazyan","year":"2018","journal-title":"J Lipid Res"},{"key":"key20210729112048_b15-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10557-008-6113-z","article-title":"Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit","volume":"22","author":"McTaggart","year":"2008","journal-title":"Cardiovasc Drugs Ther"},{"key":"key20210729112048_b16-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/01.cir.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"key20210729112048_b17-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/00365520802530861","article-title":"Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice","volume":"44","author":"Nan","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"key20210729112048_b18-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"key20210729112048_b19-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20210729112048_b20-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/dom.12809","article-title":"Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: A 1-year follow-up study","volume":"19","author":"Zhang","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"e88011","key":"key20210729112048_b21-etm-0-0-10262","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088011","article-title":"Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1","volume":"9","author":"Hoeke","year":"2014","journal-title":"PLoS One"},{"issue":"2588","key":"key20210729112048_b22-etm-0-0-10262","doi-asserted-by":"publisher","DOI":"10.3390\/nu11112588","article-title":"Polyphenol effects on cholesterol metabolism via bile acid biosynthesis, CYP7A1: A review","volume":"11","author":"Chambers","year":"2019","journal-title":"Nutrients"},{"key":"key20210729112048_b23-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"issue":"117678","key":"key20210729112048_b24-etm-0-0-10262","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117678","article-title":"Heme oxygenase-1 alleviated non-alcoholic fatty liver disease via suppressing ROS-dependent endoplasmic reticulum stress","volume":"253","author":"Li","year":"2020","journal-title":"Life Sci"},{"key":"key20210729112048_b25-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"key20210729112048_b26-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2147\/DDDT.S170518","article-title":"Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis","volume":"12","author":"Hu","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"key20210729112048_b27-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"key20210729112048_b28-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J Gastroenterol"},{"key":"key20210729112048_b29-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3803\/EnM.2016.31.4.500","article-title":"Bile acid nuclear receptor Farnesoid X receptor: Therapeutic target for nonalcoholic fatty liver disease","volume":"31","author":"Kim","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"key20210729112048_b30-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bbalip.2019.07.006","article-title":"Ursodeoxycholic acid is a GPBAR1 agonist and resets liver\/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH","volume":"1864","author":"Carino","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"key20210729112048_b31-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1499-3872(14)60009-6","article-title":"Pravastatin activates the expression of farnesoid X receptor and liver X receptor alpha in Hep3B cells","volume":"13","author":"Byun","year":"2014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"key20210729112048_b32-etm-0-0-10262","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1194\/jlr.M053124","article-title":"Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice","volume":"55","author":"Fu","year":"2014","journal-title":"J Lipid Res"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T08:20:55Z","timestamp":1627546855000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,3]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10262","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"article-number":"830"}}